GLP-1 Medications for Weight Loss Now Available!

The city of Chicago, Illinois, currently has 4 active clinical trials seeking participants for Weight Loss research studies.
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2006, Chicago, Illinois
Conditions: Weight Loss
Register for Updates
VK2735 for Weight Management Phase 3
NCT07104500
Recruiting
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1006, Chicago, Illinois +1 locations
Conditions: Weight Loss
Register for Updates
A Novel Intervention for Weight Loss in Young Adults
NCT06230744
Recruiting
Obesity and cardiometabolic risks are significant public health issues, with about two-thirds of U.S. adults overweight or obese. Weight loss can prevent these health problems, but current lifestyle interventions have limited success. New, effective strategies are needed to address this rising issue at the population level. The goal of this clinical trial is to investigate how a behavioral intervention combined with technology impacts weight loss in young adults. The main questions it aims to an... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/14/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Weight Loss
Register for Updates
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
NCT05114798
Recruiting
Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.
Gender:
ALL
Ages:
Between 45 years and 70 years
Trial Updated:
07/01/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Register for Updates